Attovia adds to biotech IPO momentum with $289M offering
Attovia adds to biotech IPO momentum with $289M offering
Attovia Therapeutics
Private
Proprietary biparatopic nanobody platform
Company Info
Recent News
Attovia's CEO aims to scratch itch opportunity with $289M IPO
Attovia Therapeutics aims to raise $289 million in an IPO to advance three immunology and inflammation drug candidates, including a bid to challenge Dupixent in itch.
Attovia's Upsized IPO Brings In $289M to Fund New Kind of Biologic for Immune Disorders
Attovia's Upsized IPO Brings In $289M to Fund New Kind of Biologic for Immune Disorders
Attovia files for IPO to take on Sanofi and Regeneron’s Dupixent
Attovia files for IPO to take on Sanofi and Regeneron’s Dupixent
Leadership Team
To be confirmed
Chief Executive Officer
To be confirmed
Chief Medical Officer
To be confirmed
Chief Scientific Officer